Glaucoma - Pipeline Review, H1 2018

  • ID: 4482760
  • Report
  • 299 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • AC Immune SA
  • Astellas Pharma Inc
  • Eyevensys SAS
  • HitGen LTD
  • MimeTech Srl
  • Oculis ehf
  • MORE
Glaucoma - Pipeline Review, H1 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Glaucoma - Pipeline Review, H1 2018, provides an overview of the Glaucoma (Ophthalmology) pipeline landscape.

Glaucoma is a disease of the eye in which fluid pressure within the eye rises. The exact cause of optic nerve damage from glaucoma is not fully understood, but involves mechanical compression and/or decreased blood flow of the optic nerve. The most important risk factors include age, elevated eye pressure, African ancestry, thin cornea, family history of glaucoma. Signs and symptoms include eye pain, nausea and vomiting (accompanying the severe eye pain), sudden onset of visual disturbance, often in low light, blurred vision and reddening of the eye.

Report Highlights:

This Pharmaceutical and Healthcare latest pipeline guide Glaucoma - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Glaucoma (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Glaucoma (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Glaucoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 1, 11, 20, 8, 58, 14 and 4 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 10 and 3 molecules, respectively.

Glaucoma (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Glaucoma (Ophthalmology).
  • The pipeline guide reviews pipeline therapeutics for Glaucoma (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Glaucoma (Ophthalmology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Glaucoma (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Glaucoma (Ophthalmology)
Reasons for Purchase:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Glaucoma (Ophthalmology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Glaucoma (Ophthalmology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AC Immune SA
  • Astellas Pharma Inc
  • Eyevensys SAS
  • HitGen LTD
  • MimeTech Srl
  • Oculis ehf
  • MORE
Introduction

Glaucoma - Overview

Glaucoma - Therapeutics Development

Glaucoma - Therapeutics Assessment

Glaucoma - Companies Involved in Therapeutics Development

Glaucoma - Drug Profiles

Glaucoma - Dormant Projects

Glaucoma - Discontinued Products

Glaucoma - Product Development Milestones

Appendix

List of Tables

Number of Products under Development for Glaucoma, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Universities/Institutes, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Glaucoma - Pipeline by AC Immune SA, H1 2018

Glaucoma - Pipeline by Advanced Refractive Technologies Inc, H1 2018

Glaucoma - Pipeline by Aerie Pharmaceuticals Inc, H1 2018

Glaucoma - Pipeline by Aerpio Therapeutics Inc, H1 2018

Glaucoma - Pipeline by Allergan Plc, H1 2018

Glaucoma - Pipeline by Altacor Ltd, H1 2018

Glaucoma - Pipeline by Amarantus Bioscience Holdings Inc, H1 2018

Glaucoma - Pipeline by Amgen Inc, H1 2018

Glaucoma - Pipeline by Annexon Inc, H1 2018

Glaucoma - Pipeline by Astellas Pharma Inc, H1 2018

Glaucoma - Pipeline by Bial - Portela & Ca SA, H1 2018

Glaucoma - Pipeline by BioAxone BioSciences Inc, H1 2018

Glaucoma - Pipeline by Bionure Farma SL, H1 2018

Glaucoma - Pipeline by Can-Fite BioPharma Ltd, H1 2018

Glaucoma - Pipeline by Chong Kun Dang Pharmaceutical Corp, H1 2018

Glaucoma - Pipeline by D. Western Therapeutics Institute Inc, H1 2018

Glaucoma - Pipeline by Dompe Farmaceutici SpA, H1 2018

Glaucoma - Pipeline by Elsalys Biotech SAS, H1 2018

Glaucoma - Pipeline by Eyevensys SAS, H1 2018

Glaucoma - Pipeline by F. Hoffmann-La Roche Ltd, H1 2018

Glaucoma - Pipeline by Fortress Biotech Inc, H1 2018

Glaucoma - Pipeline by Gene Signal International SA, H1 2018

Glaucoma - Pipeline by Glaukos Corp, H1 2018

Glaucoma - Pipeline by Graybug Vision Inc, H1 2018

Glaucoma - Pipeline by Han Wha Pharma Co Ltd, H1 2018

Glaucoma - Pipeline by Handok Inc, H1 2018

Glaucoma - Pipeline by HitGen LTD, H1 2018

Glaucoma - Pipeline by Icon Bioscience Inc, H1 2018

Glaucoma - Pipeline by ID Pharma Co Ltd, H1 2018

Glaucoma - Pipeline by InMed Pharmaceuticals Inc, H1 2018

Glaucoma - Pipeline by Inspyr Therapeutics Inc, H1 2018

Glaucoma - Pipeline by Ironwood Pharmaceuticals Inc, H1 2018

Glaucoma - Pipeline by Isarna Therapeutics GmbH, H1 2018

Glaucoma - Pipeline by Kukje Pharmaceutical Industry Co Ltd, H1 2018

Glaucoma - Pipeline by Laboratorios SALVAT SA, H1 2018

Glaucoma - Pipeline by Laboratorios Sophia SA de CV, H1 2018

Glaucoma - Pipeline by Lee's Pharmaceutical Holdings Ltd, H1 2018

Glaucoma - Pipeline by MimeTech Srl, H1 2018

Glaucoma - Pipeline by Nemus Bioscience Inc, H1 2018

Glaucoma - Pipeline by Neurim Pharmaceuticals Ltd, H1 2018

Glaucoma - Pipeline by NicOx SA, H1 2018

Glaucoma - Pipeline by NoNO Inc, H1 2018

Glaucoma - Pipeline by Novaliq GmbH, H1 2018

Glaucoma - Pipeline by Novartis AG, H1 2018

Glaucoma - Pipeline by Ocular Therapeutix Inc, H1 2018

Glaucoma - Pipeline by Oculis ehf, H1 2018

Glaucoma - Pipeline by Ohr Pharmaceutical Inc, H1 2018

Glaucoma - Pipeline by Oncolys BioPharma Inc, H1 2018

Glaucoma - Pipeline by Pivot Pharmaceuticals Inc, H1 2018

Glaucoma - Pipeline by Profarma, H1 2018

Glaucoma - Pipeline by Q BioMed Inc, H1 2018

Glaucoma - Pipeline by Quark Pharmaceuticals Inc, H1 2018

Glaucoma - Pipeline by Regeneron Pharmaceuticals Inc, H1 2018

Glaucoma - Pipeline by Santen Pharmaceutical Co Ltd, H1 2018

Glaucoma - Pipeline by Senju Pharmaceutical Co Ltd, H1 2018

Glaucoma - Pipeline by Shire Plc, H1 2018

Glaucoma - Pipeline by Sun Pharma Advanced Research Company Ltd, H1 2018

Glaucoma - Pipeline by Sylentis SAU, H1 2018

Glaucoma - Pipeline by Taejoon Pharm Co Ltd, H1 2018

Glaucoma - Pipeline by TikoMed AB, H1 2018

Glaucoma - Dormant Projects, H1 2018

List of Figures

Number of Products under Development for Glaucoma, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Number of Products by Top 10 Targets, H1 2018

Number of Products by Stage and Top 10 Targets, H1 2018

Number of Products by Top 10 Mechanism of Actions, H1 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Top 10 Molecule Types, H1 2018

Number of Products by Stage and Top 10 Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • AC Immune SA
  • Advanced Refractive Technologies Inc
  • Aerie Pharmaceuticals Inc
  • Aerpio Therapeutics Inc
  • Allergan Plc
  • Altacor Ltd
  • Amarantus Bioscience Holdings Inc
  • Amgen Inc
  • Annexon Inc
  • Astellas Pharma Inc
  • Bial - Portela & Ca SA
  • BioAxone BioSciences Inc
  • Bionure Farma SL
  • Can-Fite BioPharma Ltd
  • Chong Kun Dang Pharmaceutical Corp
  • D. Western Therapeutics Institute Inc
  • Dompe Farmaceutici SpA
  • Elsalys Biotech SAS
  • Eyevensys SAS
  • F. Hoffmann-La Roche Ltd
  • Fortress Biotech Inc
  • Gene Signal International SA
  • Glaukos Corp
  • Graybug Vision Inc
  • Han Wha Pharma Co Ltd
  • Handok Inc
  • HitGen LTD
  • Icon Bioscience Inc
  • ID Pharma Co Ltd
  • InMed Pharmaceuticals Inc
  • Inspyr Therapeutics Inc
  • Ironwood Pharmaceuticals Inc
  • Isarna Therapeutics GmbH
  • Kukje Pharmaceutical Industry Co Ltd
  • Laboratorios SALVAT SA
  • Laboratorios Sophia SA de CV
  • Lee's Pharmaceutical Holdings Ltd
  • MimeTech Srl
  • Nemus Bioscience Inc
  • Neurim Pharmaceuticals Ltd
  • NicOx SA
  • NoNO Inc
  • Novaliq GmbH
  • Novartis AG
  • Ocular Therapeutix Inc
  • Oculis ehf
  • Ohr Pharmaceutical Inc
  • Oncolys BioPharma Inc
  • Pivot Pharmaceuticals Inc
  • Profarma
  • Q BioMed Inc
  • Quark Pharmaceuticals Inc
  • Regeneron Pharmaceuticals Inc
  • Santen Pharmaceutical Co Ltd
  • Senju Pharmaceutical Co Ltd
  • Shire Plc
  • Sun Pharma Advanced Research Company Ltd
  • Sylentis SAU
  • Taejoon Pharm Co Ltd
  • TikoMed AB
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll